Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability

Zinzani, Pier Luigi

doi:10.3816/clm.2006.n.048

Cited by 6 publications

(3 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CP can result in glomerular dysfunction and tubular dysfunction. [11][12][13][14][15][16][17] The mechanism of urotoxicity of CP has been wellstudied. The mechanism of renal toxicity of CP is not clear although oxidative stress and nitrosative stress have been reported.…”

Section: Introductionmentioning

confidence: 99%

Ultrastructural changes in the rat kidney after single dose of cyclophosphamide—Possible roles for peroxisome proliferation and lysosomal dysfunction in cyclophosphamide-induced renal damage

Abraham

Isaac

2011

Hum Exp Toxicol

View full text Add to dashboard Cite

Electron microscopy was used to examine changes in the subcellular organelles of the rat kidney at different time intervals after a single exposure to cyclophosphamide (CP). The morphological changes were studied at different time points (6 hrs, 16 hrs and 24 hrs) after a single-dose administration of CP. Six rats were killed at each time intervals after the administration of CP. Saline-treated rats served as controls. CP administration resulted in alterations in various subcellular organelles including peroxisomes, lysosomes, mitochondria, and the endoplasmic reticulum (ER) of the renal tubular epithelium as well as damage to the glomerulus. The basement membrane of the glomerulus was thickened. Many podocytes were destroyed. The nucleoplasm of the endothelial cell showed fewer granularities. The tubules were distorted and the brush border was destroyed. Two striking features in the renal tubular cells are increase in number and size of the peroxisomes (peroxisome proliferation) and decrease in the number of lysosomes. The mitochondria were elongated and the number was increased in the tubules of CP-treated rats. The ER was dilated. Cell necrosis was also seen. This study is an evidence of changes in morphology of rat kidney after induction of renal damage by a single dose of CP. Since transmission electron microscopy is the highest magnification tool at present, it can be useful in estimating the degree of injury and outcome of alternative treatment strategies in the management of CP-induced renal damage after establishing a scoring system.

show abstract

Section: Introductionmentioning

confidence: 99%

Ultrastructural changes in the rat kidney after single dose of cyclophosphamide—Possible roles for peroxisome proliferation and lysosomal dysfunction in cyclophosphamide-induced renal damage

Abraham

Isaac

2011

Hum Exp Toxicol

View full text Add to dashboard Cite

show abstract

“…[40,[82][83][84][85][86][87][88][89][90][91][92] In addition to the regimens listed in table I, there are many others that may be used alone or in combinations, including carmustine, etoposide, ifosfamide, carboplatin, cisplatin, cytarabine or cladribine. [28,93] Single-agent therapy with chlorambucil or cyclophosphamide has been viewed as less toxic and potentially more tolerable for elderly or frail patients. [93] …”

Section: Chemotherapymentioning

confidence: 99%

“…[28,93] Single-agent therapy with chlorambucil or cyclophosphamide has been viewed as less toxic and potentially more tolerable for elderly or frail patients. [93] …”

Section: Chemotherapymentioning

confidence: 99%

Economic Burden of Follicular Non-Hodgkinʼs Lymphoma

Foster¹,

Miller²,

Boye

et al. 2009

PharmacoEconomics

View full text Add to dashboard Cite

Follicular non-Hodgkin's lymphoma (FNHL), a slow-growing cancer of the immune system, constitutes about 15-30% of all incident non-Hodgkin's lymphoma in developed countries. Its incidence is rising worldwide. Patients can live many years, but FNHL is considered incurable. We systematically reviewed the English-language MEDLINE-indexed and non-indexed economic literature published in the past 10 years on FNHL, identifying 23 primary economic studies. The economic burden of FNHL is significant, but available data are generally limited to retrospective considerations of hospital-based direct treatment costs, with little information available regarding societal cost of illness. Most direct cost information originates from the US, with one estimate of $US36 000 for the per-patient incremental cost of FNHL care during the first year following diagnosis. The most studied treatment is rituximab, which may offer similar overall costs to fludarabine considering higher resource use with fludarabine complications. Nearly all cost-effectiveness models identified by this review evaluated rituximab for relapsed/refractory FNHL responding to chemotherapy induction. Rituximab is supported as a cost-effective addition to standard chemotherapy by two models in the UK and one in the US, as maintenance therapy instead of stem-cell transplant by one UK model, and as maintenance therapy instead of observation alone by one model each in France, Spain and Canada. The UK National Institute for Health and Clinical Excellence updated guidance on rituximab in February 2008, concluding that it is cost effective when added to induction chemotherapy, and when used as maintenance therapy. No studies of per-patient or national indirect costs of illness were identified, with the only study of indirect costs a Canadian survey documenting lost work productivity. Across all study types identified by our review, the most common focus was on the direct costs of rituximab. As new treatments for FNHL come to market, more real-life cost data are imperative to calculate their relative cost effectiveness.

show abstract

Current Awareness in Hematological Oncology

2007

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Reviews; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability

Cited by 6 publications

References 92 publications

Ultrastructural changes in the rat kidney after single dose of cyclophosphamide—Possible roles for peroxisome proliferation and lysosomal dysfunction in cyclophosphamide-induced renal damage

Ultrastructural changes in the rat kidney after single dose of cyclophosphamide—Possible roles for peroxisome proliferation and lysosomal dysfunction in cyclophosphamide-induced renal damage

Economic Burden of Follicular Non-Hodgkinʼs Lymphoma

Current Awareness in Hematological Oncology

Contact Info

Product

Resources

About